IntelGenx Corp. Announces Public Offering Of $3,500,000 Of Common Stock

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAINT LAURENT, Quebec, Dec. 12, 2013 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilmâ„¢ technology, as well as oral controlled-release products, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $3.5 million of securities in a registered public offering. IntelGenx has agreed to sell to institutional investors an aggregate of 7,920,346 shares of its common stock at $0.4419 per share. Additionally, investors will receive warrants to purchase up to 7,920,346 shares of common stock at an exercise price of $0.5646 per share for a term of five years.

Help employers find you! Check out all the jobs and post your resume.

Back to news